Clinical Trials
22 trialsROTATE
Yale University
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
EMAT
Medical College of Wisconsin
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
NIRVANA
Columbia University
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Risk-adapted Therapeutic Strategy in +1q NDMM
The First Hospital of Jilin University
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
MRD-CONFIRM
Assistance Publique - Hôpitaux de Paris
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
MRD
The First Hospital of Jilin University
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
First Affiliated Hospital of Zhejiang University
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
ctDNA Methylation Sequencing for Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
MMRD
Hospices Civils de Lyon
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
University Hospital, Montpellier
EUCADD
Shanghai Changzheng Hospital